Under the agreement, Pall will establish a suspension-based manufacturing platform of up to 2,000 L using a variety of technologies including Pall's Allegro single-use bioreactors. The new platform will enable the production of viral vectors for a variety of gene therapies, as well as for vector-based vaccines, the company said.

Exothera selected Pall's end-to-end solution based on its flexibility and capability to scale processes quickly and efficiently, according to Vasily Medvedev, Exothera's head of development. The company will utilize the new platform technology in its new good manufacturing practice (GMP) facilities near Brussels, which are expected to begin production this summer.

Exothera adds continuous upstream bioprocessing tech to services
Contract development and manufacturing organization Exothera has acquired the NevoLine Upstream manufacturing platform, the latest equipment available...

Pall debuts solution for biotech research
Pall, one of the largest suppliers of laboratory filtration and clarification products, recently launched two new filtration and clarification plates...